149 related articles for article (PubMed ID: 37107543)
1. T-Cell Receptor Repertoire Characteristics Associated with Prognostic Significance in High-Grade Serous Ovarian Carcinoma.
Kim JW; Kim S; Yang SY; Joung JG; Hwang S
Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107543
[TBL] [Abstract][Full Text] [Related]
2. Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis.
Yang B; Li X; Zhang W; Fan J; Zhou Y; Li W; Yin J; Yang X; Guo E; Li X; Fu Y; Liu S; Hu D; Qin X; Dou Y; Xiao R; Lu F; Wang Z; Qin T; Wang W; Zhang Q; Li S; Ma D; Mills GB; Chen G; Sun C
Cell Rep Med; 2022 Dec; 3(12):100856. PubMed ID: 36543113
[TBL] [Abstract][Full Text] [Related]
3. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
4. Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer.
Shu T; Zhou Z; Bai J; Xiao X; Gao M; Zhang N; Wang H; Xia X; Gao Y; Zheng H
Gynecol Oncol; 2023 Jan; 168():135-143. PubMed ID: 36442424
[TBL] [Abstract][Full Text] [Related]
5. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
Cole DJ; Wilson MC; Rivoltini L; Custer M; Nishimura MI
Cancer Res; 1997 Dec; 57(23):5320-7. PubMed ID: 9393756
[TBL] [Abstract][Full Text] [Related]
6. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
[TBL] [Abstract][Full Text] [Related]
7. Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes.
Zhu S; Zhang C; Cao D; Bai J; Yu S; Chen J; Wang J; Ren T; Yang J; Yu M; Xiao X; Gong Y; Guan Y; Li P; Yue Y; Yin R; Wang Y; An R; Lou G; Yuan J; Zhang G; Xia X; Yang L; Xiang Y
Oncogene; 2022 May; 41(22):3093-3103. PubMed ID: 35468938
[TBL] [Abstract][Full Text] [Related]
8. Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer.
Yoshida-Court K; Karpinets TV; Mitra A; Solley TN; Dorta-Estremera S; Sims TT; Delgado Medrano AY; El Alam MB; Ahmed-Kaddar M; Lynn EJ; Sastry KJ; Zhang J; Futreal A; Nick A; Lu K; Colbert LE; Klopp AH
PLoS One; 2023; 18(1):e0279590. PubMed ID: 36607962
[TBL] [Abstract][Full Text] [Related]
9. TCR repertoire intratumor heterogeneity of CD4
Zhang C; Ding H; Huang H; Palashati H; Miao Y; Xiong H; Lu Z
Int J Cancer; 2019 Feb; 144(4):818-827. PubMed ID: 30151844
[TBL] [Abstract][Full Text] [Related]
10. Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer.
Zhang G; Xu Q; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
Cancer Med; 2021 Jun; 10(12):3905-3918. PubMed ID: 33955198
[TBL] [Abstract][Full Text] [Related]
11. Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer.
Tsuji T; Eng KH; Matsuzaki J; Battaglia S; Szender JB; Miliotto A; Gnjatic S; Bshara W; Morrison CD; Lele S; Emerson RO; Wang J; Liu S; Robins H; Lugade AA; Odunsi K
Oncotarget; 2020 Jul; 11(27):2669-2683. PubMed ID: 32676168
[TBL] [Abstract][Full Text] [Related]
12. TCR Repertoire as a Novel Indicator for Immune Monitoring and Prognosis Assessment of Patients With Cervical Cancer.
Cui JH; Lin KR; Yuan SH; Jin YB; Chen XP; Su XK; Jiang J; Pan YM; Mao SL; Mao XF; Luo W
Front Immunol; 2018; 9():2729. PubMed ID: 30524447
[TBL] [Abstract][Full Text] [Related]
13. Biophysicochemical motifs in T cell receptor sequences as a potential biomarker for high-grade serous ovarian carcinoma.
Ostmeyer J; Lucas E; Christley S; Lea J; Monson N; Tiro J; Cowell LG
PLoS One; 2020; 15(3):e0229569. PubMed ID: 32134923
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
15. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
Takaya H; Nakai H; Takamatsu S; Mandai M; Matsumura N
Sci Rep; 2020 Feb; 10(1):2757. PubMed ID: 32066851
[TBL] [Abstract][Full Text] [Related]
16. Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
Wallbillich JJ; Morris RT; Ali-Fehmi R
Gynecol Oncol; 2020 Nov; 159(2):381-386. PubMed ID: 32900500
[TBL] [Abstract][Full Text] [Related]
17. Differences in immune-related gene expressions and tumor-infiltrating lymphocytes according to chemotherapeutic response in ovarian high-grade serous carcinoma.
Choi KU; Kim A; Kim JY; Kim KH; Hwang C; Lee SJ; Park WY; Jung S; Choi HJ; Kim K
J Ovarian Res; 2020 Jun; 13(1):65. PubMed ID: 32513298
[TBL] [Abstract][Full Text] [Related]
18. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
[TBL] [Abstract][Full Text] [Related]
19. Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype.
van Wilpe S; Simnica D; Slootbeek P; van Ee T; Pamidimarri Naga S; Gorris MAJ; van der Woude LL; Sultan S; Koornstra RHT; van Oort IM; Gerritsen WR; Kroeze LI; Simons M; van Leenders GJLH; Binder M; de Vries IJM; Mehra N
Oncoimmunology; 2022; 11(1):2094133. PubMed ID: 35800157
[TBL] [Abstract][Full Text] [Related]
20. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
Pinto MP; Balmaceda C; Bravo ML; Kato S; Villarroel A; Owen GI; Roa JC; Cuello MA; Ibañez C
Gynecol Oncol; 2018 Oct; 151(1):10-17. PubMed ID: 30078505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
